- Home
- TRVI vs XPEL Comparison
TRVI vs XPEL Comparison
Compare TRVI & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | XPEL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TRVI | XPEL |
|---|---|---|
| Price | $11.86 | $39.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $20.38 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 249.5K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.12 |
| EPS | N/A | ★ 1.85 |
| Revenue | N/A | ★ $476,200,000.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | N/A | $11.98 |
| P/E Ratio | ★ N/A | $21.79 |
| Revenue Growth | N/A | ★ 13.27 |
| 52 Week Low | $4.85 | $24.27 |
| 52 Week High | $14.39 | $55.91 |
Technical Indicators
Market Signals| Indicator | TRVI | XPEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 24.15 |
| Support Level | $10.04 | $35.10 |
| Resistance Level | $12.11 | $55.36 |
| Average True Range (ATR) | 0.70 | 2.27 |
| MACD | 0.17 | -0.95 |
| Stochastic Oscillator | 53.89 | 5.53 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.